OS Therapies Inc
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On June 24, 2026, Paul A. Romness, our Chairman, President and Chief Executive Officer adopted a written Rule 10b5-1 trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 600,000 shares of our common stock, subject to certain price limits. Sales under the plan are scheduled to commence on September 23, 2026, and the plan is scheduled toexpire on September 23, 2027, subject to early termination in accordance with the terms of the plan.
No other director or officer of our company adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.